09:07 AM EDT, 04/08/2024 (MT Newswires) -- The parent of drugmaker Novo Nordisk ( NVO ) has resubmitted an application for US regulatory approval of its $16.5 billion acquisition bid for medicine production outsourcing firm Catalent ( CTLT ) , a regulatory filing last week has shown.

A spokesperson for Novo Nordisk Foundation said the refiling aims "to give authorities more time," Reuters reported on Monday.

The Novo Nordisk Foundation said last month that it had agreed to purchase Catalent ( CTLT ) and merge three of the medicine outsourcing firm's pill-making plants with Novo Nordisk ( NVO ).

Novo Nordisk ( NVO ) applied for federal approval of the merger on March 4, withdrew, and submitted a new application a few days ago, the April 3 proxy statement submitted by Catalent ( CTLT ) to the US Securities and Exchange Commission has shown.

"Novo Nordisk Foundation's notification and report form was withdrawn and refiled effective as of April 2, 2024, at which time a new 30-calendar-day waiting period commenced," the proxy statement said.

Price: 126.88, Change: +1.01, Percent Change: +0.81